The role of thrombin in the pathogenesis of diabetic neuropathy.
Diabetic neuropathy is common and disabling despite glycemic control. Novel neuroprotective approaches are needed. Thrombin and hypercoagulability are associated with diabetes and nerve conduction dysfunction. Our aim was to study the role of thrombin in diabetic neuropathy. We measured thrombin act...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0219453 |
id |
doaj-9ce70936db294acf80919875da1ef7e7 |
---|---|
record_format |
Article |
spelling |
doaj-9ce70936db294acf80919875da1ef7e72021-03-03T20:35:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01147e021945310.1371/journal.pone.0219453The role of thrombin in the pathogenesis of diabetic neuropathy.Efrat Shavit-SteinRamona AronovichConstantin SylantievShany Guly GofritJoab ChapmanAmir DoriDiabetic neuropathy is common and disabling despite glycemic control. Novel neuroprotective approaches are needed. Thrombin and hypercoagulability are associated with diabetes and nerve conduction dysfunction. Our aim was to study the role of thrombin in diabetic neuropathy. We measured thrombin activity by a biochemical assay in streptozotocin (STZ)-induced diabetic neuropathy in male Sprague-Dawley rats. Neuropathy severity was assessed by thermal latency and nerve conduction measures. Thermal latencies were longer in diabetic rats, and improved with the non-specific serine-protease inhibitor Tosyl-L-lysine-chloromethyl ketone (TLCK) treatment (p<0.01). The tail nerve of diabetic rats showed slow conduction velocity (p˂0.01), and interestingly, increased thrombin activity was noted in the sciatic nerve (p˂0.001). Sciatic nodes of Ranvier and the thrombin receptor, protease activated receptor 1 (PAR1) reactivity showed abnormal morphology in diabetic animals by immunofluorescence staining (p<0.0001). Treatment of diabetic animals with either the specific thrombin inhibitor, N-alpha 2 naphtalenesulfonylglycyl alpha-4 amidino-phenylalaninepiperidide (NAPAP) or TLCK preserved normal conduction velocity, (p˂0.01 and p = 0.01 respectively), and prevented disruption of morphology (p˂0.05 and p˂0.03). The results establish for the first time an association between diabetic neuropathy and excessive activation of the thrombin pathway. Treatment of diabetic animals with thrombin inhibitors ameliorates both biochemical, structural and electrophysiological deficits. The thrombin pathway inhibition may be a novel neuroprotective therapeutic target in the diabetic neuropathy pathology.https://doi.org/10.1371/journal.pone.0219453 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Efrat Shavit-Stein Ramona Aronovich Constantin Sylantiev Shany Guly Gofrit Joab Chapman Amir Dori |
spellingShingle |
Efrat Shavit-Stein Ramona Aronovich Constantin Sylantiev Shany Guly Gofrit Joab Chapman Amir Dori The role of thrombin in the pathogenesis of diabetic neuropathy. PLoS ONE |
author_facet |
Efrat Shavit-Stein Ramona Aronovich Constantin Sylantiev Shany Guly Gofrit Joab Chapman Amir Dori |
author_sort |
Efrat Shavit-Stein |
title |
The role of thrombin in the pathogenesis of diabetic neuropathy. |
title_short |
The role of thrombin in the pathogenesis of diabetic neuropathy. |
title_full |
The role of thrombin in the pathogenesis of diabetic neuropathy. |
title_fullStr |
The role of thrombin in the pathogenesis of diabetic neuropathy. |
title_full_unstemmed |
The role of thrombin in the pathogenesis of diabetic neuropathy. |
title_sort |
role of thrombin in the pathogenesis of diabetic neuropathy. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
Diabetic neuropathy is common and disabling despite glycemic control. Novel neuroprotective approaches are needed. Thrombin and hypercoagulability are associated with diabetes and nerve conduction dysfunction. Our aim was to study the role of thrombin in diabetic neuropathy. We measured thrombin activity by a biochemical assay in streptozotocin (STZ)-induced diabetic neuropathy in male Sprague-Dawley rats. Neuropathy severity was assessed by thermal latency and nerve conduction measures. Thermal latencies were longer in diabetic rats, and improved with the non-specific serine-protease inhibitor Tosyl-L-lysine-chloromethyl ketone (TLCK) treatment (p<0.01). The tail nerve of diabetic rats showed slow conduction velocity (p˂0.01), and interestingly, increased thrombin activity was noted in the sciatic nerve (p˂0.001). Sciatic nodes of Ranvier and the thrombin receptor, protease activated receptor 1 (PAR1) reactivity showed abnormal morphology in diabetic animals by immunofluorescence staining (p<0.0001). Treatment of diabetic animals with either the specific thrombin inhibitor, N-alpha 2 naphtalenesulfonylglycyl alpha-4 amidino-phenylalaninepiperidide (NAPAP) or TLCK preserved normal conduction velocity, (p˂0.01 and p = 0.01 respectively), and prevented disruption of morphology (p˂0.05 and p˂0.03). The results establish for the first time an association between diabetic neuropathy and excessive activation of the thrombin pathway. Treatment of diabetic animals with thrombin inhibitors ameliorates both biochemical, structural and electrophysiological deficits. The thrombin pathway inhibition may be a novel neuroprotective therapeutic target in the diabetic neuropathy pathology. |
url |
https://doi.org/10.1371/journal.pone.0219453 |
work_keys_str_mv |
AT efratshavitstein theroleofthrombininthepathogenesisofdiabeticneuropathy AT ramonaaronovich theroleofthrombininthepathogenesisofdiabeticneuropathy AT constantinsylantiev theroleofthrombininthepathogenesisofdiabeticneuropathy AT shanygulygofrit theroleofthrombininthepathogenesisofdiabeticneuropathy AT joabchapman theroleofthrombininthepathogenesisofdiabeticneuropathy AT amirdori theroleofthrombininthepathogenesisofdiabeticneuropathy AT efratshavitstein roleofthrombininthepathogenesisofdiabeticneuropathy AT ramonaaronovich roleofthrombininthepathogenesisofdiabeticneuropathy AT constantinsylantiev roleofthrombininthepathogenesisofdiabeticneuropathy AT shanygulygofrit roleofthrombininthepathogenesisofdiabeticneuropathy AT joabchapman roleofthrombininthepathogenesisofdiabeticneuropathy AT amirdori roleofthrombininthepathogenesisofdiabeticneuropathy |
_version_ |
1714821676215042048 |